Form DEF 14A Bio-Techne Corp For: 7 July By Investing.com
This article announces the filing of Form DEF 14A by Bio-Techne Corp on July 7, 2026. The content provides basic financial market data, including various indices, commodities, and stock performances, alongside a brief mention of the specific SEC filing for Bio-Techne.
Merck KGaA secures $11.3 billion purchase of Bio-Techne
This article is a placeholder with a title indicating Merck KGaA's acquisition of Bio-Techne for $11.3 billion. No content beyond the title is provided, so further details about the acquisition are unavailable.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: LCI Industries (NYSE – LCII), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH), Arcosa, Inc. (NYSE – ACA)
Brodsky & Smith is investigating potential breaches of fiduciary duties by the Boards of Directors of LCI Industries (LCII), Iridium Communications Inc. (IRDM), Bio-Techne Corporation (TECH), and Arcosa, Inc. (ACA) regarding their proposed acquisitions. The investigations focus on whether the boards conducted a fair process and if the offered consideration provides fair value to shareholders in each respective transaction. Investors are encouraged to contact Brodsky & Smith for discussions about these investigations.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of
Brodsky & Smith LLC is notifying investors of investigations into four companies: LCI Industries (LCII), Iridium Communications Inc. (IRDM), Bio-Techne Corporation (TECH), and Arcosa, Inc. (ACA). The investigations concern potential breaches of fiduciary duties by the companies' Boards related to proposed mergers, questioning whether fair value is being paid to shareholders. Investors are encouraged to contact the firm if they own shares in these companies.
Evercore ISI Adjusts Price Target on Thermo Fisher Scientific to $570 From $575
Evercore ISI has adjusted its price target for Thermo Fisher Scientific (NYSE: TMO) to $570, a slight decrease from its previous target of $575. The article highlights other recent news concerning Thermo Fisher, including collaborations and analyst recommendations. Thermo Fisher Scientific specializes in laboratory and scientific equipment, diagnostics, and related services, with significant operations in North America and Europe.
Evercore ISI Downgrades Bio-Techne to In Line From Outperform, Maintains $73 Price Target
Evercore ISI has downgraded Bio-Techne (NASDAQ: TECH) to "In Line" from "Outperform," while keeping its price target at $73. This follows similar downgrades from other firms like Piper Sandler, Benchmark, TD Cowen, and Citigroup, many of whom also set price targets around $73. Bio-Techne specializes in manufacturing products for life science research, including biological and chemical reagents, analysis tools, and diagnostic and genomics products.
Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion
Merck KGaA is reportedly planning to acquire Bio-Techne for $11.3 billion, aiming to expand its presence in the life science sector. This strategic acquisition signifies Merck KGaA's commitment to strengthening its portfolio and market position.
Bio-Techne will be sold for $11.3B, one of largest deals in Minnesota history
The article reports that Bio-Techne, a Minnesota-based company, is set to be acquired for $11.3 billion. This acquisition represents one of the largest deals in Minnesota's history, highlighting a significant transaction within the state's business landscape.
BLFS - Biolife Solutions Inc Options
This article provides comprehensive financial data and stock performance metrics for Biolife Solutions Inc. (BLFS), including its last close price, market capitalization, income, sales, key financial ratios, EPS, and insider/institutional ownership details. It also features various performance indicators over different timeframes and analyst recommendations.
Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) regarding potential breaches of fiduciary duty related to its recently announced $11.3 billion transaction with Merck. The investigation focuses on whether Bio-Techne shareholders are receiving a fair price of $73 per share, given that insiders benefit from change of control arrangements and the transaction agreement includes a significant penalty for competing bids. Ademi LLP encourages shareholders to join their investigation to determine if the board fulfilled its fiduciary duties.
Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for potential breaches of fiduciary duty and other legal violations following its announced transaction with Merck, valued at approximately $11.3 billion. The investigation focuses on whether the Bio-Techne board is upholding its fiduciary duties to all shareholders, particularly given the $73 per share cash offer and significant benefits for insiders, alongside contractual limitations on competing bids. Shareholders are invited to join the investigation to determine if a fair price is being obtained.
AstraZeneca PLC Stock (AZN) Moved Down by 3.02% on Jul 1: What Investors Need To Know
AstraZeneca PLC (AZN) stock dropped by 3.02% on July 1st due to a combination of clinical trial failures, regulatory delays for new therapies, and a broad market rotation out of defensive pharmaceutical stocks into cyclical sectors. The company's experimental anti-fibril therapy failed its Phase III clinical program, and the FDA extended its review for an oral breast cancer therapy, contributing to investor caution. Additionally, the emergence of AI platforms for drug discovery has led investors to reassess traditional pharmaceutical valuations.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: LCI Industries (NYSE – LCII), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH), Arcosa, Inc. (NYSE – ACA)
Brodsky & Smith is investigating potential breaches of fiduciary duties by the Boards of LCI Industries (LCII), Iridium Communications Inc. (IRDM), Bio-Techne Corporation (TECH), and Arcosa, Inc. (ACA) in connection with their respective acquisition agreements. The investigations focus on whether the proposed transactions offer fair value to shareholders and if due process was followed. Shareholders are encouraged to contact the firm for more information without cost or obligation.
TD Cowen Downgrades Bio-Techne to Hold From Buy, Adjusts Price Target to $73 From $65
TD Cowen has downgraded Bio-Techne (NASDAQ: TECH) from a "Buy" rating to a "Hold" rating. Concurrently, the firm adjusted its price target for Bio-Techne shares to $73, up from the previous target of $65. This change in rating and target price reflects a revised outlook from the financial institution regarding the company's stock.
Bio-Techne Up Over 19%, on Pace for Largest Percent Increase Since May 2003 -- Data Talk
Bio-Techne Corp. shares are experiencing a significant surge, climbing over 19% and set to record their largest percentage increase since May 2003. This positive movement is attributed to strong earnings and revenue performance in the second quarter, both of which surpassed analyst expectations. The company also raised its full-year revenue growth outlook, further boosting investor confidence.
Bio-Techne Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Bio-Techne Corporation - TECH
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Bio-Techne Corporation (NasdaqGS: TECH) to Merck KGaA for $73.00 per share in cash. The law firm is examining whether this consideration and the process leading to the sale are adequate or if the Company is undervalued. Shareholders who believe the transaction undervalues Bio-Techne are encouraged to contact KSF to discuss their legal rights.
Enterprise value to EBIT forward of Bio-Techne Corporation – MIL:1TECH
This article provides a financial snippet for Bio-Techne Corporation (MIL:1TECH) on TradingView, specifically focusing on its enterprise value to EBIT forward. The content indicates that no trades have occurred for the company at market close. The page is part of TradingView's platform, offering financial data and community features.
Merck KGaA to acquire U.S.-based Bio-Techne Corp. for $11.3 billion
Merck KGaA announced its definitive agreement to acquire Bio-Techne Corp. for $11.3 billion, or $73 per share in cash, representing a 36% premium. This acquisition aims to strengthen Merck KGaA's position in high-growth life sciences areas like multi-omics, spatial biology, and cell and gene therapy, by combining Bio-Techne's innovative portfolio with Merck KGaA's global scale and manufacturing expertise. The transaction, approved by both boards, is expected to close by late 2026 or early 2027, pending regulatory and shareholder approvals, and will be funded through existing cash and new debt while maintaining a strong investment-grade credit rating.
Enterprise value to EBITDA forward of Bio-Techne Corporation – FWB:TE1
The article provides financial data for Bio-Techne Corporation (FWB:TE1), specifically its enterprise value to EBITDA forward. It indicates the market status as closed with no trades and shows the current period value, change, and percentage change for this metric.
Merck KGaA acquires Bio-Techne for $11.7bn
Merck KGaA is set to acquire Bio-Techne Corporation for $11.3 billion, paying $73 per share in cash. This acquisition aims to strengthen Merck's position in high-growth life science areas such as multi-omics, spatial biology, precision diagnostics, and cell and gene therapy, aligning with its long-term strategic agenda of scaling innovation through M&A. The deal, expected to close by late 2026 or early 2027, will be funded by cash and new debt, anticipating immediate accretion to sales growth and EBITDA pre-margin post-closing, along with €140 million in annual cost synergies.
Enterprise value to EBITDA forward of Bio-Techne Corporation – SWB:TE1
This article provides financial information for Bio-Techne Corporation (SWB:TE1) on the Stuttgart Stock Exchange, specifically focusing on its enterprise value to EBITDA forward. The page displays the current financial status and market data for the company.
Merck KGaA to acquire Bio-Techne in $11.3bn deal to strengthen life sciences leadership
Merck KGaA has agreed to acquire Bio-Techne Corporation for approximately $11.3 billion, paying $73 per share in cash. This strategic acquisition aims to expand Merck's presence in high-growth life sciences markets such as multi-omics, spatial biology, and cell and gene therapy. The deal, expected to close in late 2026 or early 2027, is projected to generate significant cost synergies and bolster Merck's Life Science division across research, development, and manufacturing.
Merck KGaA to acquire Bio-Techne in $11.3bn deal to strengthen life sciences leadership
Merck KGaA announced its definitive agreement to acquire U.S.-based Bio-Techne Corporation for $11.3 billion (€9.9 billion) to expand its presence in high-growth life sciences markets. This acquisition, expected to close in late 2026 or early 2027, will broaden Merck's capabilities in areas like multi-omics, spatial biology, and cell and gene therapy, leveraging Bio-Techne's expertise and Merck's global reach. Merck anticipates significant financial benefits, including €140 million in annual cost synergies and positive impact on sales growth, EBITDA margin, and earnings per share.
Merck KGaA to acquire Bio-Techne in $11.3 billion deal
Merck KGaA has announced its intention to acquire Bio-Techne in an estimated $11.3 billion deal. This acquisition is poised to significantly expand Merck KGaA's presence and capabilities in the biotechnology and life science sectors. Further details regarding the strategic rationale and financial implications are expected to follow.
Merck KGaA’s $11.3 Billion Bet on Bio-Techne Redraws the Map of Life-Science Tools
Merck KGaA is set to acquire Bio-Techne Corporation for approximately $11.3 billion, marking its largest acquisition since 2014 and a significant move into the high-margin biological content sector. This deal aims to bolster Merck's life science division by adding Bio-Techne's extensive catalogue of proteins and antibodies, along with analytical platforms vital for early-stage research and cell/gene therapy workflows. The acquisition reflects a broader industry trend of consolidation within the life-science tools sector, emphasizing integrated workflows and recurring revenue streams.
Weekly Market Update: Stocks Slip 1.86% as Healthcare Rises and Technology Falls
The Morningstar US Market Index dropped 1.86% this week, primarily due to a significant fall in the technology sector, while healthcare and real estate sectors saw substantial gains. Blackberry, Bayer, and Bio-Techne were among the top stock gainers, whereas ON Semiconductor, Arm, and Bloom Energy were among the biggest losers. The article also provides bond and commodity market updates and a look at upcoming economic data releases.
5 Best Electrical Equipment Stocks to Buy According to Analysts
This article identifies five top electrical equipment stocks favored by analysts, selecting those with at least a 20% consensus upside on price targets. It starts by highlighting Array Technologies, Inc. and its new DuraTrack D2S solar tracker, detailing its features and market impact. The piece focuses on companies contributing to electrification hardware and solar project efficiency.
Piper Sandler Highlights Intuitive Surgical (ISRG) on Long-Term Growth Catalysts
Piper Sandler has reiterated an Overweight rating and a $580 price target for Intuitive Surgical (ISRG), based on recent field checks confirming positive sentiment. The firm identifies several growth catalysts for ISRG, including the potential in ambulatory surgery centers, DV5 cardiovascular treatments, and My Intuitive+. Furthermore, recent upgrades to the da Vinci 5 robotic surgical system are expected to enhance Intuitive Surgical's market position, reinforcing the company's strong fundamentals despite prevailing concerns.
Merck KGaA throws down $11.3B for Bio-Techne in its biggest deal since 2015 Sigma-Aldrich buy
Merck KGaA is acquiring Bio-Techne Corporation for approximately $11.3 billion, representing its largest deal since the 2015 Sigma-Aldrich buyout. This acquisition, led by new CEO Kai Beckmann, aims to strengthen Merck KGaA's life sciences division and expand its capabilities in life-sci tools, analytical technologies, and cell and gene therapy workflows. The deal is expected to close by late 2026 or early 2027 and will integrate Bio-Techne's portfolio and manufacturing expertise with Merck KGaA's global scale.
Evercore ISI Turns Bullish on Canadian National Railway (CNI), Upgrades Stock to Outperform
Evercore ISI has upgraded Canadian National Railway (CNI) to Outperform from In Line, raising its price target to $124 from $108. Analyst Jonathan Chappell believes CNI is poised for a "material beat & raise" in its Q2 earnings due to conservative guidance and positive volume momentum. RBC Capital also recently raised its price recommendation on CNI to C$195, citing strong earnings upside potential and favorable network dynamics.
Bio-Techne (TECH) Soars 20% on Merck $11.3B Merger
Bio-Techne (NASDAQ:TECH) shares surged 20.08% after the company announced an $11.3 billion all-cash merger with pharmaceutical giant Merck. The agreement, priced at $73 per share, represents a 24% premium over Bio-Techne's previous closing price. Both companies anticipate completing the transaction by late 2026 or early 2027, subject to regulatory and shareholder approvals.
Bio-Techne agrees to $11.3 billion buyout by Germany's Merck
Germany's Merck KGaA is set to acquire Bio-Techne for $11.3 billion. This represents a 36% premium over Bio-Techne's recent trading price. The deal is anticipated to be finalized by late 2026 or early 2027.
Bio-Techne to Be Acquired by Merck KGaA
Merck KGaA announced a proposed acquisition of Bio-Techne on June 25, 2026, with the deal expected to close by late 2026 or early 2027. Bio-Techne is a leader in proteins, immunoassays, clinical diagnostic controls, and other crucial reagents for academic, biopharmaceutical, and diagnostic markets. Jay Lee, a stock analyst, provided this assessment in a note.
IQiyii stock ahead of Thursday, shares and consensus in view
This article provides an overview of iQIYI Inc. (NASDAQ: IQ) ahead of Thursday's trading, focusing on analyst and market context. It highlights the company's NASDAQ listing, its position within the US tech and media peer group, and how broader market sentiment and analyst coverage on profitability and cash generation typically influence the stock. The core product of iQIYI, a Chinese streaming company, is its platform offering subscription video, advertising, and original content.
Merck & Co Inc Stock (MRK) Moved Up by 4.04% on Jun 25: A Full Analysis
Merck & Co Inc (MRK) stock rose by 4.04% due to major regulatory approvals for its oncology drug Keytruda and pneumococcal vaccine Capvaxive, boosting future revenue prospects. Analysts have also turned bullish, citing strong financial guidance and dividend reliability, despite concerns over Keytruda's patent expiration and other pipeline setbacks.
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating several companies—Bio-Techne Corporation (TECH), Apogee Therapeutics, Inc. (APGE), Boundless Bio, Inc. (BOLD), and Chicago Atlantic Real Estate Finance, Inc. (REFI)—for potential violations of federal securities laws and breaches of fiduciary duties related to their recent sales or mergers. The firm suggests that insiders might receive financial benefits not available to ordinary shareholders and that transaction terms could limit superior competing offers. Shareholders are encouraged to contact the law firm to discuss their rights and options.
Bio-Techne Corp. stock outperforms competitors on strong trading day
Bio-Techne Corp. (TECH) stock saw a significant gain of 20.08% to $70.70 on Thursday, marking its third consecutive day of increases. This performance occurred during a mixed trading session where the Dow Jones Industrial Average rose slightly, and the S&P 500 Index experienced a minor decline. The article highlights Bio-Techne's strong outperformance relative to the broader market and its competitors.
Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) regarding potential breaches of fiduciary duty related to its recently announced transaction with Merck. Shareholders are set to receive $73 per share in cash, valuing the company at $11.3 billion, but the law firm is examining whether this constitutes a fair price, especially given benefits for insiders and restrictions on competing bids. Ademi LLP encourages Bio-Techne shareholders to contact them to learn more about the investigation.
Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for potential breaches of fiduciary duty due to its recently announced transaction with Merck, where shareholders would receive $73 per share in cash. The firm is examining whether the $11.3 billion enterprise value represents a fair price given the substantial benefits to Bio-Techne insiders and a significant penalty imposed on competing transactions. Shareholders are encouraged to contact Ademi LLP to learn more about joining the investigation.
Merck buying Twin Cities medtech firm Bio-Techne for $11.3B
Merck is set to acquire Minneapolis-based Bio-Techne Corp. for $11.3 billion, a move that comes after activist investor pressure for Bio-Techne to sell. Merck's new CEO, Kai Beckmann, stated that this acquisition aligns with their strategy to deliver cutting-edge products across the industry value chain. Bio-Techne's CEO, Kim Kelderman, believes the deal will offer greater scale and capabilities to accelerate innovation.
Merck Germany Lands Bio-Techne In $11.3 Billion Cash Deal
Merck KGaA is acquiring Bio-Techne for $11.3 billion in an all-cash deal, offering Bio-Techne shareholders $73 per share, a 36% premium. This acquisition aligns with Merck's strategy to expand its life science capabilities in high-growth areas, particularly in spatial biology, diagnostics, and cell and gene therapy. The transaction is expected to close in late 2026 or early 2027, with anticipated annual cost synergies of about 140 million euros.
Quanterix Corp sets out growth plans, shares trade on Nasdaq
Quanterix Corp is gaining investor attention with its digital biomarker platform and recent operational milestones, with its shares trading on Nasdaq. The company focuses on developing ultra-sensitive digital biomarker assays based on its proprietary Simoa technology, targeting pharmaceutical and academic research as well as diagnostic partners. Quanterix generates revenue through the sale of Simoa instruments, consumable assay kits, and related services, emphasizing collaborations to expand assay menus and stabilize revenue streams.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
This article lists 12 healthcare stocks experiencing significant movement in pre-market trading on Thursday. It details both gainers like Adicet Bio, Bio-Techne, and TELA Bio, noting their percentage increase and market values. Conversely, it also highlights decliners such as ARS Pharmaceuticals and Passage Bio, providing their percentage decrease and market capitalization.
S&P 500 Futures Climb in Premarket Trading; Bio-Techne, Micron Technology Lead
S&P 500 futures showed a premarket climb, led by significant gains in Bio-Techne Corp. (TECH) and Micron Technology Inc. (MU). Bio-Techne was up 20.9%, while Micron Technology saw a 17.7% increase in pre-market trading as U.S. stock markets prepared to open.
Bio-Techne (TECH) Surges 22% on Merck KGaA Acquisition Offer
Bio-Techne (TECH) shares surged over 22% in premarket trading after Merck KGaA announced a $73 per share cash acquisition, valuing the deal at approximately $11.3 billion. This offer represents a 36% premium and reflects Merck's confidence in Bio-Techne's future growth potential. Bio-Techne, a life sciences manufacturer with a strong market presence, exhibits robust financial health and profitability, though insider selling activity has been noted.
Merck to Acquire Bio-Techne for $73 Per Share in $11.3B Deal
Germany's Merck KGaA announced its acquisition of U.S. biotech firm Bio-Techne Corp for $11.3 billion, offering $73 per share, a 24% premium over Bio-Techne's closing price. This strategic move aims to expand Merck's presence in the life sciences market by gaining access to Bio-Techne's research reagents, proteins, antibodies, and analytical instruments. The deal, Merck's largest life sciences acquisition since 2014, is expected to close by late 2026 or early 2027 and will be financed through a combination of cash and debt.
Bio-Techne surges over 22% in premarket on takeover deal
The article reports that Bio-Techne's stock price surged over 22% in premarket trading. This significant increase is attributed to a takeover deal.
Germany's Merck to buy Bio-Techne for $11.3 billion
Germany's Merck KGaA has announced its acquisition of biotech firm Bio-Techne Corp for $11.3 billion, representing a 24% premium over Bio-Techne's closing price on Wednesday. This strategic move aims to expand Merck's presence in life-science research, as Bio-Techne supplies essential research reagents and tools. The acquisition will be financed through a combination of existing cash and new debt.
Germany’s Merck to buy Bio-Techne for $73 per share By Reuters
Germany's Merck KGaA announced its agreement to acquire biotech firm Bio-Techne Corp for $73 per share in an all-cash deal. This acquisition represents a total enterprise value of approximately $11.3 billion. The offer price reflects a 36% premium over Bio-Techne’s one-month volume-weighted average share price.
Merck KGaA: Merck Agrees to Acquire Bio-Techne Corporation
Merck KGaA has announced its definitive agreement to acquire Bio-Techne Corporation for US$73 per share in cash, totaling approximately US$11.3 billion (EUR 9.9 billion). Bio-Techne is a global provider of life science tools, and the acquisition, subject to regulatory and shareholder approvals, offers a 36% premium to Bio-Techne's one-month volume-weighted average trading price. Merck plans to fund the acquisition through existing cash and new debt while maintaining a strong investment-grade credit rating.
